1. A method of treating a wart in a subject, the method comprising

identifying a subject having or suspected of having a wart; and

administering to the subject a composition comprising a fusion protein comprising (1) a heat shock protein (hsp) or an immunostimulatory fragment thereof, and (2) a protein of a human papilloma virus (HPV), or an antigenic fragment thereof, wherein the composition is administered in an amount sufficient to treat the wart.

2. The method of claim 1, wherein the hsp is a mycobacterial hsp.

3. The method of claim 2, wherein the mycobacterial hsp is a *Mycobacterium bovis hsp*.

4. The method of claim 3, wherein the hsp is *Mycobacterium bovis* Hsp65.

5. The method of claim 1, wherein the hsp is a member of the Hsp60 or Hsp70 family of proteins.

6. The method of claim 1, wherein the HPV is a type 16 HPV.

7. The method of claim 1, wherein the protein of the HPV is an E7 protein.

8. The method of claim 1, wherein the composition contains about 50 to 5000 μg of the fusion protein.

9. The method of claim 8, wherein the composition contains about 100 to 2000 μg of the fusion protein.

10. The method of claim 1, wherein the composition is administered free of adjuvant.

11. The method of claim 1, wherein the subject is a mammal.

12. The method of claim 11, wherein the mammal is a human.

13. The method of claim 1, wherein the fusion protein is administered in an amount sufficient to reduce the size of the wart.

14. A method of treating, in a subject, a disease or condition associated with a human papilloma virus (HPV), the method comprising

administering to the subject a composition comprising a fusion protein comprising (1) an hsp, or an immunostimulatory fragment thereof, and (2) a protein of an HPV, or an antigenic fragment thereof, wherein the subject is infected with an HPV type that is different from the HPV type administered to the subject, the composition being administered in an amount sufficient to treat the disease or condition.

15. The method of claim 14, wherein the hsp is a mycobacterial hsp.

16. The method of claim 15, wherein the mycobacterial hsp is a *Mycobacterium bovis* hsp.

17. The method of claim 16, wherein the hsp is *Mycobacterium bovis* Hsp65.

18. The method of claim 14, wherein the hsp is a member of the Hsp60 or Hsp70 family of proteins.

19. The method of claim 14, wherein the HPV type administered to the subject is type 16.

20. The method of claim 19, wherein the subject has a disease or condition associated with an HPV of type 5, 6, 11, 18, 31, 33, 35, 45, 54, 60, or 70.

21. The method of claim 20, wherein the subject has a disease or condition associated with an HPV of type 6, 11, 33, 45, or 70.

22. The method of claim 21, wherein the subject has a disease or condition associated with an HPV of type 6 or 11.

23. The method of claim 14, wherein the protein of the HPV is an E7 protein.

24. The method of claim 14, wherein the composition contains about 50 to 5000 μg of the fusion protein.

25. The method of claim 24, wherein the composition contains about 100 to 2000 μg of the fusion protein.

26. The method of claim 14, wherein the composition is free of adjuvant.

27. The method of claim 14, wherein the subject is a mammal.

28. The method of claim 27, wherein the mammal is a human.

29. The method of claim 14, wherein the subject is not identified as being infected with the type of HPV that is administered prior to administration of the composition.

30. A method of treating a wart in a subject, the method comprising

identifying a subject having, or suspected of having, a wart;

administering to the subject a nucleic acid encoding a fusion polypeptide comprising (1) an hsp, or an immunostimulatory fragment thereof, and (2) a protein of an HPV or an antigenic fragment thereof; and

expressing the fusion polypeptide in the subject in an amount sufficient to treat the wart.

31. The method of claim 30, wherein the nucleic acid is contained within a viral vector.

32. A method of treating, in a subject, a disease or condition associated with an HPV infection, the method comprising:

administering to the subject a nucleic acid encoding a fusion protein comprising (1) an hsp, or an immunostimulatory fragment thereof, and (2) a protein of an HPV, wherein the subject is infected with an HPV type that is different from the HPV type administered to the subject; and

expressing the fusion protein in the subject in an amount sufficient to treat the disease or condition.

33. The method of claim 32, wherein the nucleic acid is contained within a viral vector.

34. The method of claim 14, wherein the disease or condition is anogenital warts, plantars warts, cervical cancer, cervical dysplasia, anal cancer, anal dysplasia, or recurrent respiratory papillomatosis.

35. The method of claim 32, wherein the disease or condition is anogenital warts, plantars warts, cervical cancer, cervical dysplasia, anal cancer, anal dysplasia, or recurrent respiratory papillomatosis.